Benzinga | Aug 14, 2020 05:18AM EDT

SVB Leerink Maintains Outperform on Trevi Therapeutics, Raises Price Target to $9

SVB Leerink maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $8 to $9.